Lantheus to present data on PET imaging agents at SNM meeting

05/19/2010 | (free registration)

Lantheus Medical Imaging said it will present initial data from a Phase II trial of its myocardial perfusion PET imaging agent, flurpiridaz F-18, at the upcoming SNM meeting. The company also will present Phase I results on its LMI1195 cardiac neuronal PET imaging agent.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA